ACR Meeting Abstracts

ACR Meeting Abstracts

  • Meetings
    • ACR Convergence 2024
    • ACR Convergence 2023
    • 2023 ACR/ARP PRSYM
    • ACR Convergence 2022
    • ACR Convergence 2021
    • ACR Convergence 2020
    • 2020 ACR/ARP PRSYM
    • 2019 ACR/ARP Annual Meeting
    • 2018-2009 Meetings
    • Download Abstracts
  • Keyword Index
  • Advanced Search
  • Your Favorites
    • Favorites
    • Login
    • View and print all favorites
    • Clear all your favorites
  • ACR Meetings

Abstracts tagged "Behcet’s syndrome"

  • Abstract Number: 1797 • 2018 ACR/ARHP Annual Meeting

    An Update on Pulmonary Artery Involvement in Behcet’s Syndrome: More Pulmonary Artery Thrombotic Disease and a Better Outcome

    Yesim Ozguler1, Elif Dincses2, Selim Bakan3, Gulen Hatemi1, Melike Melikoglu1, Sebahattin Yurdakul1, Hasan Yazici1 and Emire Seyahi1, 1Istanbul University, Cerrahpasa Medical Faculty, Department of Internal Medicine, Division of Rheumatology, Istanbul, Turkey, 2Istanbul University, Cerrahpasa Medical Faculty, Department of Internal Medicine, Division of Rheumatology, İstanbul, Turkey, 3Istanbul University, Cerrahpasa Medical Faculty, Department of Radiology, ISTANBUL, Turkey

    Background/Purpose: Pulmonary artery involvement (PAI) is the most common form of arterial involvement in Behçet’s syndrome (BS). A previous survey (1) by our group had…
  • Abstract Number: 1975 • 2018 ACR/ARHP Annual Meeting

    Behcet’s Disease Lies in the “B” Holder. New Associations in Disease Susceptibility and Manifestations

    Mohanad Elfishawi1,2, Sally Elfishawi3, Ghada Mossallam3, Paul Norman4, Jill Hollenbach5, Maneesh Misra5, Gonzalo Montero Martin6, Helma de Bruin7, Leos Van de Pasch7, Erik Rozemuller7, Marcelo Fernandiz-Vina6, Adriana Abrudescu8 and Khaled Zaky9, 1Internal Medicine, Icahn School of Medicine at Mount Sinai, Queens Hospital Center, New York, NY, 2Rheumatology, Kasr Alainy Hospital, Cairo University, Cairo, Egypt, 3Clinical pathology and Immunology laboatory, National Cancer Institute, Cairo University, Cairo, Egypt, 4Division of Personalized Medicine and Department of Immunology, University of Colorado School of Medicine, Denver, CO, 5Department of Neurology, University of California San Francisco, San Francisco, CA, 6Department of Pathology, Stanford University,School of medicine, Palo Alto, CA, 7GenDx, Utrecht, Netherlands, 8Internal Medicine and Rheumatology, Icahn School of Medicine at Mount Sinai, Queens Hospital center, NYC, NY, 9Rheumatology and Rehabilitation, Faculty of medicine, Al-Azhar University, Cairo, Egypt

    Background/Purpose: Behçet’s disease is a multisystem disease affecting young adults with variable vessel vasculitis as its underlying pathology. Previous studies in Behçet’s disease linked it…
  • Abstract Number: 1798 • 2018 ACR/ARHP Annual Meeting

    Leg Ulcers in Behçet’s Syndrome: An Observational Survey in 24 Patients

    Yesim Ozguler1, Zekayi Kutlubay2, Atilla Süleyman Dikici3, Melike Melikoglu1, Cem Mat2, Hasan Yazici1 and Emire Seyahi1, 1Istanbul University, Cerrahpasa Medical Faculty, Department of Internal Medicine, Division of Rheumatology, Istanbul, Turkey, 2Istanbul University, Cerrahpasa Medical Faculty, Department of Dermatology, Istanbul, Turkey, 3Radiolgy, Istanbul University, Cerrahpasa Medical Faculty, Department of Radiology, Istanbul, Turkey

     Background/Purpose: Formal experience with leg ulcers in Behcet’s syndrome (BS) is limited. It is a relatively rare complication that can be seen during the course…
  • Abstract Number: 2166 • 2018 ACR/ARHP Annual Meeting

    Treatment of Venous Thrombotic Events in Behçet Disease: A Systematic Literature Review

    Iustina Janta1, Roberto González2, Tania Gudu3 and Indalecio Monteagudo1, 1Rheumatology, Hospital General Universitario Gregorio Marañón, Madrid, Spain, 2Rheumatology, Hospital general Universitario Gregorio Marañón, Madrid, Spain, 3University of Medicine Carol Davila Bucuresti, Romania, Bucuresti, Romania

    Background/Purpose: Venous thrombosis (VT) is a serious and potentially life-threatening manifestation of Behçet disease (BD). However, there is little evidence of the management of the…
  • Abstract Number: 1799 • 2018 ACR/ARHP Annual Meeting

    Increased Vein Wall Thickness in Behçet’s Syndrome

    Migena Gjoni1, Serkan Akbaş2, Emine Şebnem Durmaz2, Atilla Süleyman Dikici2, İsmail Mihmanlı2, Hasan Yazici3 and Emire Seyahi4, 1Istanbul University, Cerrahpasa Medical Faculty, Department of Internal Medicine, Istanbul, Turkey, 2Radiolgy, Istanbul University, Cerrahpasa Medical Faculty, Department of Radiology, Istanbul, Turkey, 3Istanbul Academic Hospital, Istanbul, Turkey, 4Istanbul University, Cerrahpasa Medical Faculty, Department of Internal Medicine, Division of Rheumatology, Istanbul, Turkey

    Background/Purpose: Lower extremity vein thrombosis (LEVT) is the key feature of vascular involvement in Behçet’s syndrome (BS).Vein wall thickness (VWT) is proposed to be a…
  • Abstract Number: 2269 • 2018 ACR/ARHP Annual Meeting

    Infliximab Therapy in Refractory Retinal Vasculitis of Behçet’s Disease, Short and Long-Term Follow-up. Multicenter Study of 72 Patients

    José Luis Martín-Varillas1, Belén Atienza-Mateo1, Vanesa Calvo-Río2, Diana Prieto Peña2, Monica Calderón Goercke2, Rosalía Demetrio-Pablo3, Javier Loricera3, M. Victoria Hernández4, Alfredo Adan5, Marina Mesquida5, Diana Peiteado6, David Diaz-Valle7, Lucía Martínez-Costa8, Elia Valls-Pascual8, Miguel A. Caracuel9, Angel Garcia-Aparicio10, Jose M Herreras11, Miguel Cordero-Coma12, Carlos Alberto Montilla-Morales13, Alejandro Fonollosa14, Antonio Atanes15, Félix Francisco16, Ignacio Torre-Salaberri17, Olga Maíz18, Ana Blanco19, Cruz Fernandez-Espartero20, Norberto Ortego Centeno21, Enrique Raya Álvarez22, Myriam Gandía23, Francisco Javier López Longo24, Maria Alcalde-Villar25, Cristina Fernández-Carballido26, Esperanza Pato Cour27, Oscar Ruiz Moreno28, Fernando Jiménez-Zorzo29, Raquel Almodóvar González30, Carmen Carrasco-Cubero31, Luis Francisco Linares32, Fredeswinda I. Romero-Bueno33, Santos Insua34, Senen González-Suárez35, Marisa Hernández36, Emma Beltrán37, Juan Cruz38, Carlos Férnandez Cid39, Elena Aurrecoechea40, Enar Pons1, Miguel Angel González-Gay3 and Ricardo Blanco1, 1Rheumatology, Hospital Universitario Marqués de Valdecilla. IDIVAL. Santander. Universidad de Cantabria. Spain, Santander, Spain, 2Rheumatology, Rheumatology. Hospital Universitario Marqués de Valdecilla. IDIVAL. Santander. Universidad de Cantabria. Spain, Santander, Spain, 3Hospital Universitario Marqués de Valdecilla. IDIVAL. Santander. Universidad de Cantabria. Spain, Santander, Spain, 4Rheumatology, Hospital Clinic. Barcelona. Spain, Barcelona, Spain, 5Hospital Clinic. Barcelona. Spain, Barcelona, Spain, 6Rheumatology, Rheumatology, La Paz University Hospital, Madrid, Spain, 7Hospital Clínico San Carlos. Madrid. Spain, Madrid, Spain, 8Hospital Universitario Doctor Peset. Valencia. Spain, Valencia, Spain, 9Hospital de Córdoba, Córdoba, Spain., Córdoba, Spain, 10Rheumatology, Hospital de Toledo. Toledo. Spain, Toledo, Spain, 11Ophthalmology, Hospital Universitario, IOBA. Valladolid. Spain, Valladolid, Spain, 12Ophthalmology, Hospital de León. Spain, León, Spain, 13Hospital Clínico Universitario de Salamanca. Spain, Salamanca, Spain, 14Ophthalmology, Hospital de Cruces. Bilbao. Spain, Bilbao, Spain, 15Complejo Hospitalario Universitario A Coruña. Spain, A Coruna, Spain, 16Rheumatology, Hospital Doctor Negrín. Las Palmas de Gran Canaria. Spain, Las Palmas de Gran Canaria, Spain, 17Rheumatology, Hospital Universitario de Basurto. Bilbao. Spain, Bilbao, Spain, 18Hospital Universitario Donostia. San Sebastian. Spain, San Sebastián, Spain, 19Ophtamology, Hospital Universitario Donostia. San Sebastian. Spain, San Sebastian, Spain, 20Rheumatology, Hospital de Móstoles. Madrid. Spain, Madrid, Spain, 21Medicine Department, Hospital Universitario San Cecilio. Granada. Spain, Granada, Spain, 22Rheumatology, Hospital Universitario San Cecilio. Granada. Spain, Granada, Spain, 23Rheumatology, Hospital Puerta del Mar. Cádiz. Spain, Cádiz, Spain, 24Rheumatology Department, Hospital General Universitario Gregorio Marañón, Madrid, Spain, 25Hospital Severo Ochoa, Madrid, Spain, Madrid, Spain, 26Rheumatology Division, Hospital General Universitario de Elda, Elda, Spain, 27Rheumatology, Hospital Clínico San Carlos, Madrid, Spain, 28Ophthalmology and Rheumatology, Hospital Miguel Servet. Zaragoza. Spain, Zaragoza, Spain, 29Hospital Miguel Servet. Zaragoza. Spain, Zaragoza, Spain, 30Rheumatology, Hospital Universitario Fundación Alcorcón. Madrid. Spain, Madrid, Spain, 31Hospital de Mérida. Spain, Mérida, Spain, 32Rheumatology, Hospital Virgen de la Arrixaca. Murcia. Spain, Murcia, Spain, 33Section for Autoimmune Diseases, Rheumatology, Fundación Jiménez Díaz University Hospital & Health Research Institute, Madrid, Spain, 34Rheumatology, Hospital Universitario Santiago de Compostela. La Coruña. Spain, La Coruña, Spain, 35Rheumatology, Hospital de Cabueñes. Gijón. Spain, Gijón, Spain, 36Ophthalmology, Hospital General Universitario de Valencia. Spain, Valencia, Spain, 37Rheumatology, Hospital del Mar. Barcelona. Spain, Barcelona, Spain, 38Hospital de Pontevedra. Pontevedra. Spain, Pontevedra, Spain, 39Ophthalmology, Hospital de Pontevedra. Pontevedra. Spain, Pontevedra, Spain, 40Rheumatology, Hospital de Sierrallana, Torrelavega. Cantabria. Spain, Torrelavega, Spain

    Background/Purpose: Retinal vasculitis is a serious complication of uveitis due to Behçet’s disease (BD). The treatment is based on corticosteroids, conventional immunosuppressants (IS) and anti-TNF-α…
  • Abstract Number: 1801 • 2018 ACR/ARHP Annual Meeting

    Factors Associated with Damage Progression in Behçet’s Syndrome Uveitis

    Yilmaz Ozyazgan1, Didar Ucar2, Mustafa Erdogan3, Yesim Ozguler3, Gulen Hatemi4, Sebahattin Yurdakul3, Vedat Hamuryudan3, Izzet Fresko3, Melike Melikoglu5, Emire Seyahi3, Serdal Ugurlu3 and Hasan Yazici6, 1Istanbul University, Cerrahpasa Medical Faculty, Department of Ophthalmology, Istanbul, Turkey, 2Ophthalmology, Istanbul University, Cerrahpasa Medical Faculty, Department of Ophthalmology, Istanbul, Turkey, 3Istanbul University, Cerrahpasa Medical Faculty, Department of Internal Medicine, Division of Rheumatology, Istanbul, Turkey, 4Division of Rheumatology, Department of Internal Medicine, Cerrahpasa Medical Faculty, University of Istanbul, Istanbul, Turkey, 5Istanbul University Cerrahpasa Medical School, Istanbul, Turkey, 6Division of Rheumatology,, Cerrahpasa Medical Faculty, University of Istanbul, Istanbul, Turkey

    Background/Purpose: Uveitis in Behçet’s syndrome (BS) follows a recurrent disease course with inflammatory exacerbations causing damage in the uvea, retina and optic nerve even with…
  • Abstract Number: 2789 • 2018 ACR/ARHP Annual Meeting

    Efficacy of Apremilast for Oral Ulcers Associated with Active Behçet’s Syndrome over 28 Weeks: Results from a Phase III Study

    Gulen Hatemi1, Alfred Mahr2, Yoshiaki Ishigatsubo3, Yeong Wook Song4, Melike Melikoglu5, Sue Cheng6, Shannon McCue6, Maria Paris6, Mindy Chen6 and Yusuf Yazici7, 1Rheumatology, Istanbul University, Cerrahpasa Medical School, Istanbul, Turkey, 2Hospital Saint-Louis, University Paris Diderot, Paris, France, 3Yokohama City University Graduate School of Medicine, Yokohama, Japan, 4Rheumatology, Seoul National University Hospital, Seoul, Korea, Republic of (South), 5Istanbul University Cerrahpasa Medical School, Istanbul, Turkey, 6Celgene Corporation, Summit, NJ, 7New York University School of Medicine, New York, NY

    Background/Purpose: Behçet’s syndrome is a chronic, relapsing, multi-system inflammatory disorder characterized by recurrent oral ulcers (OU), which can be disabling and substantially impact quality of…
  • Abstract Number: 1802 • 2018 ACR/ARHP Annual Meeting

    Behcet’s Disease in the Southwestern United States

    Maheswari Muruganandam1 and Noelle Rolle2, 1Rheumatology, University of New Mexico Health Sciences Center, ALBUQUERQUE, NM, 2Rheumatology, University Of New Mexico Health Sciences Center, ALBUQUERQUE, NM

    Background/Purpose: Behcet’s disease (BD) in the US is estimated to have a prevalence of 5.2-6.6 per 100,000 populations which is similar to that of European…
  • Abstract Number: 2841 • 2018 ACR/ARHP Annual Meeting

    Apremilast for Behçet’s Syndrome: Results from a Phase III, Randomized, Double-Blind, Placebo-Controlled Study in a Japanese Subgroup

    Mitsuhiro Takeno1, Yoshiya Tanaka2, Hajime Kono3, Shouji Sugii4, Mitsumasa Kishimoto5, Sue Cheng6, Shannon McCue6, Maria Paris6 and Hiroaki Dobashi7, 1Nippon Medical School Graduate School of Medicine, Tokyo, Japan, 2University of Occupational and Environmental Health, Kitakyushu, Japan, 3Department of Internal Medicine, Teikyo University School of Medicine, Tokyo, Japan, 4Department of Rheumatology, Tokyo Metropolitan Tama Medical Center, Tokyo, Japan, 5Immuno-Rheumatology Center, St. Luke's International Hospital, Tokyo, Japan, 6Celgene Corporation, Summit, NJ, 7Internal Medicine Division of Hematology, Rheumatology, and Respiratory Medicine, Kagawa University, Kagawa, Japan

    Background/Purpose: Apremilast, an oral phosphodiesterase 4 inhibitor, demonstrated efficacy in a global, phase III, multicenter, randomized, double-blind, placebo-controlled study in patients with Behçet’s syndrome and…
  • Abstract Number: 149 • 2018 ACR/ARHP Annual Meeting

    Deep Immune-Profiling of CD4+ T Cells in Behçet’s Disease

    Johannes Nowatzky1, Arshed Al-Obeidi2, Yuhe Xia2 and Olivier Manches3, 1Department of Medicine, Division of Rheumatology, NYU School of Medicine, New York, NY, 2NYU School of Medicine, New York, NY, 3INSERM, Grenoble, France

    Background/Purpose: Functionality and immune-phenotypes of the human CD4+ T-cell compartment in Behçet’s disease (BD) are under-investigated, but several lines of evidence point to its relevance…
  • Abstract Number: 1804 • 2018 ACR/ARHP Annual Meeting

    Optimization Protocol for Adalimumab Treatment in Refractory Uveitis Due to Behçet’s Disease

    José Luis Martín-Varillas1, Belén Atienza-Mateo1, Vanesa Calvo-Río2, Diana Prieto Peña2, Monica Calderón Goercke2, Eva Peña Sainz-Pardo3, Emma Beltrán4, Juan Sánchez Bursón Sr.5, M. Victoria Hernández6, Alfredo Adan7, Marina Mesquida7, Marisa Hernández8, Elia Valls-Pascual9, Lucía Martínez-Costa9, Agusti Sellas-Fernandez10, Miguel Cordero-Coma11, Manuel Díaz-Llopis12, Roberto Gallego12, David Salom12, Norberto Ortego Centeno13, Jose L. García Serrano14, José-Luis Callejas-Rubio15, Jose M Herreras16, Angel Garcia-Aparicio17, Olga Maíz18, Ana Blanco19, Ignacio Torre-Salaberri20, David Diaz-Valle21, Esperanza Pato Cour22, Elena Aurrecoechea23, Miguel A. Caracuel24, Fernando Gamero25, Enrique Minguez26, Carmen Carrasco-Cubero27, Alejandro Olivé-Marqués28, Oscar Ruiz Moreno29, Javier Manero29, Julio Vázquez30, Santiago Muñoz Fernandez31, Myriam Gandía32, Esteban Rubio-Romero33, Francisco Toyos34, Francisco Javier López Longo35, Joan Miquel Nolla36, Marcelino Revenga Martínez37, Javier Loricera3, Rosalía Demetrio-Pablo3, Enar Pons1, José Luis Hernández3, Miguel Angel González-Gay3 and Ricardo Blanco1, 1Rheumatology, Hospital Universitario Marqués de Valdecilla. IDIVAL. Santander. Universidad de Cantabria. Spain, Santander, Spain, 2Rheumatology, Rheumatology. Hospital Universitario Marqués de Valdecilla. IDIVAL. Santander. Universidad de Cantabria. Spain, Santander, Spain, 3Hospital Universitario Marqués de Valdecilla. IDIVAL. Santander. Universidad de Cantabria. Spain, Santander, Spain, 4Rheumatology, Hospital del Mar. Barcelona. Spain, Barcelona, Spain, 5Rheumatology, Hospital de Valme. Sevilla. Spain, Sevilla, Spain, 6Rheumatology, Hospital Clinic. Barcelona. Spain, Barcelona, Spain, 7Hospital Clinic. Barcelona. Spain, Barcelona, Spain, 8Ophthalmology, Hospital General Universitario de Valencia. Spain, Valencia, Spain, 9Hospital Universitario Doctor Peset. Valencia. Spain, Valencia, Spain, 10Vall d'Hebron Hospital Research Institute, Barcelona, Spain, 11Ophthalmology, Hospital de León. Spain, León, Spain, 12Hospital Universitario La Fe. Valencia. Spain, Valencia, Spain, 13Medicine Department, Hospital Universitario San Cecilio. Granada. Spain, Granada, Spain, 14Ophthalmology, Hospital Universitario San Cecilio. Granada. Spain, Granada, Spain, 15Hospital Universitario San Cecilio. Granada. Spain, Granada, Spain, 16Ophthalmology, Hospital Universitario, IOBA. Valladolid. Spain, Valladolid, Spain, 17Rheumatology, Hospital de Toledo. Toledo. Spain, Toledo, Spain, 18Hospital Universitario Donostia. San Sebastian. Spain, San Sebastián, Spain, 19Ophtamology, Hospital Universitario Donostia. San Sebastian. Spain, San Sebastian, Spain, 20Rheumatology, Hospital Universitario de Basurto. Bilbao. Spain, Bilbao, Spain, 21Hospital Clínico San Carlos. Madrid. Spain, Madrid, Spain, 22Rheumatology, Hospital Clínico San Carlos, Madrid, Spain, 23Rheumatology, Hospital de Sierrallana, Torrelavega. Cantabria. Spain, Torrelavega, Spain, 24Hospital de Córdoba, Córdoba, Spain., Córdoba, Spain, 25Rheumatology, Hospital San Pedro Alcántara. Cáceres. Spain, Cáceres, Spain, 26Ophthalmology, Hospital Clínico de Zaragoza. Spain, Zaragoza, Spain, 27Hospital de Mérida. Spain, Mérida, Spain, 28Rheumatology, Hospital Universitari Germans Trias i Pujol, Badalona, Spain, 29Ophthalmology and Rheumatology, Hospital Miguel Servet. Zaragoza. Spain, Zaragoza, Spain, 30Rheumatology, Hospital de Ferrol. La Coruña. Spain, La Coruña, Spain, 31Hospital Universitario Infanta Sofía. Madrid. Spain, San Sebastián de los Reyes (Madrid), Spain, 32Rheumatology, Hospital Puerta del Mar. Cádiz. Spain, Cádiz, Spain, 33Hospital Universitario Virgen del Rocío. Sevilla. Spain, Sevilla, Spain, 34Rheumatology, Hospital Universitario Virgen de la Macarena, Sevilla, Spain, 35Rheumatology Department, Hospital General Universitario Gregorio Marañón, Madrid, Spain, 36Rheumatology, Hospital Universitario de Bellvitge, Barcelona, Spain, 37Hospital Universitario Ramón y Cajal. Madrid. Spain, Madrid, Spain

    Background/Purpose: Uveitis is the most common ocular manifestation in Behçet Disease (BD), which can cause irreversible blindness. Once the efficacy, safety and cost-effectiveness of Adalimumab…
  • Abstract Number: 2993 • 2018 ACR/ARHP Annual Meeting

    Vascular Involvement in Behcet’s Syndrome May be Associated with Subclinical Atherosclerosis

    Emine USLU YURTERI1, EVREN ÜSTÜNER2, Murat TORGUTALP1, Mucteba Enes YAYLA1, Ilyas Ercan OKATAN1, Ayse Bahar KELESOGLU DINCER1, Serdar SEZER1, Emine Gozde AYDEMIR GULOKSUZ1, Tahsin Murat TURGAY1, Gülay KINIKLI3 and Aşkın Ateş4, 1Department of Internal Medicine, Division of Rheumatology, Ankara University School of Medicine Department of Internal Medicine, Division of Rheumatology, ANKARA, Turkey, 2RADIOLOGY, ANKARA UNIVERSITY RADIOLOGY DEPARTMENT, ANKARA, Turkey, 3Department of Internal Medicine, Division of Rheumatology, Ankara University School of Medicine Department of Internal Medicine, Division of Rheumatology, Ankara, Turkey, 4Department of Internal Medicine, Division of Rheumatology, Ankara University School of Medicine, Ankara, Turkey

    Background/Purpose: Behçet's Syndrome (BS) is a vasculitic process which is characterized by recurrent oral and genital aphthous ulcerations, ocular, vascular, neurological, and gastrointestinal involvement .…
  • Abstract Number: 918 • 2018 ACR/ARHP Annual Meeting

    A Novel Familial RELA Truncation Is Associated with Behçet’s-like Mucocutaneous Ulceration Syndrome

    Emma Dorris1, Fahd Adeeb2, Eoin Cummins3, Sinisa Savic4, Sandy Fraser5 and Anthony G. Wilson6, 1UCD Conway Institute,, UCD Centre for Arthritis Research, Dublin 4, Ireland, 2Department of Rheumatology, University of Limerick, LIMERICK, Ireland, 3School of Medicine, Dublin 4, Ireland, 4Leeds Institute of Rheumatic and Musculoskeletal Medicine, The University of Leeds, Leeds, United Kingdom, 5Rheumatology, Croom Orthopedic Hospital, Ireland, Limerick, Ireland, 6UCD School of Medicine and Medical Science, Conway Institute, University College Dublin, Dublin, Ireland

    Background/Purpose: Bechet’s disease (BD) is a heterogeneous multifactorial auto-inflammatory condition characterized by recurrent episodes of oral and genital ulceration, uveitis and skin lesions, with less…
  • Abstract Number: 1805 • 2018 ACR/ARHP Annual Meeting

    Strong Association of HLA-DRB1*0901 with Japanese Patients with Chronic Progressive Neuro-Behçet’s Disease

    Hirotoshi Kikuchi1, Takafumi Tomizuka1, Takahiro Itamiya1, Kurumi Asako1, Tamiko Yanagida1, Hajime Kono2 and Shunsei Hirohata3, 1Department of Internal Medicine, Teikyo University School of Medicine, Tokyo, Japan, 2Teikyo University School of Medicine, Department of Internal Medicine, Tokyo, Japan, 3Department of Rheumatology and Infectious Diseases, Kitasato University School of Medicine, Sagamihara, Japan

    Background/Purpose: Central nervous system involvement is one of the most serious complications in Behçetfs disease (BD). This condition is referred to as neuro-BD (NB) and…
  • « Previous Page
  • 1
  • 2
  • 3
  • 4
  • 5
  • …
  • 12
  • Next Page »
Advanced Search

Your Favorites

You can save and print a list of your favorite abstracts during your browser session by clicking the “Favorite” button at the bottom of any abstract. View your favorites »

All abstracts accepted to ACR Convergence are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 10:00 AM ET on November 14, 2024. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].

Wiley

  • Online Journal
  • Privacy Policy
  • Permissions Policies
  • Cookie Preferences

© Copyright 2025 American College of Rheumatology